Guselkumab is safe and effective in patients with moderate-to-severe Crohn’s disease

1. The Guselkumab group demonstrated significantly greater clinical and endoscopic responses versus placebo. 2. Serious adverse events were comparable, with no treatment-related deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: Despite the availability of biological therapies, many patients with Crohn’s disease experience suboptimal disease control. This randomized controlled trial aimed to evaluate the efficacy and […]